Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism

Journal of Clinical Endocrinology and Metabolism

Volumn 80, Issue 6, 1995, Pages 1816-1821

  Oelkers, W ^a   Foidart, J M ^c   Dombrovicz, N ^c   Welter, A ^d   Heithecker, R ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b BAYER PHARMA AG   (Germany)

^c Hospital de Baviere   (Belgium)

^d Laboratoire du Vieux Mayeur ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; DROSPIRENONE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MINERALOCORTICOID ANTAGONIST; ORAL CONTRACEPTIVE AGENT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE TOLERANCE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; LIPID BLOOD LEVEL; LIPID METABOLISM; MASTALGIA; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN SUBSTRATE; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION;

BIOLOGY; BLOOD PRESSURE--CHANGES; BODY WEIGHT--CHANGES; CARBOHYDRATE METABOLIC EFFECTS; CLINICAL RESEARCH; CONTRACEPTION; CONTRACEPTION RESEARCH; CONTRACEPTIVE AGENTS; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE AGENTS, PROGESTIN; CONTRACEPTIVE METHODS--PHARMACODYNAMICS; CONTRACEPTIVE METHODS--SIDE EFFECTS; DEVELOPED COUNTRIES; EUROPE; FAMILY PLANNING; GERMANY; GLUCOSE METABOLISM EFFECTS; HEMIC SYSTEM; LIPID METABOLIC EFFECTS; LIPIDS; METABOLIC EFFECTS; ORAL CONTRACEPTIVES, COMBINED--PHARMACODYNAMICS; ORAL CONTRACEPTIVES, COMBINED--SIDE EFFECTS; ORAL CONTRACEPTIVES--PHARMACODYNAMICS; ORAL CONTRACEPTIVES--SIDE EFFECTS; PHYSIOLOGY; RESEARCH METHODOLOGY; RESEARCH REPORT; WESTERN EUROPE;

ADOLESCENT; ADULT; ALDOSTERONE; ANDROSTENES; ANGIOTENSIN I; BLOOD PRESSURE; BODY WEIGHT; CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; LIPIDS; MINERALOCORTICOIDS; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0029011362     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jcem.80.6.7775629     Document Type: Article

References (27)

1. Weir RJ. 1978 When the pill causes a rise in blood pressure. Drugs 16:522-527.
2. Crane MG, Harris JJ. 1978 Estrogens and hypertension: effect of discontinuing estrogens on blood pressure, exchangeable sodium and the renin-aldosterone system. Am J Med Sci. 276:33-55.
3. WHO. 1989 The WHO multicenter trial of the vasopressor effects of combined oral contraceptives. I. Comparison with 1UD. Contraception. 40:129-145.
4. WHO. 1989 The WHO multicenter trial of the vasopressor effects of combined oral contraceptives. II. Lack of effect of estrogen. Contraception. 40:147-156.
5. McAreavey D, Cumming AMM, Boddy K, et al. 1983 The renin-angiotensin system and total body sodium and potassium in hypertensive women taking estrogen-progestagen oral contraceptives. Clin Endocrinol (Oxf). 18:111-118.
6. Petitti DB, Klatsky AL. 1983 Malignant hypertension in women aged 15 to 44 years and its relation to cigarette smoking and oral contraceptives. Am J Cardiol. 52:297-298.
7. Lim KG, Isles CG, Hodsman GP, Lever AF, Robertson JIS. 1987 Malignant hypertension in women of childbearing age and its relation to the contraceptive pill. Br Med J. 294:1057-1059.
8. Godsiand IF, Crook D, Simpson R, et al. 1990 The effect of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med. 323:1375-1381.
9. Gaspard UJ. 1991 Clinical relevance of plasma lipid changes during use of new Iow-dose oral contraceptives. Adv Contraception. 7(Suppl 1):180-194.
10. Oelkers W, Berger V, Bolik A, et al. 1991 Dihydrospirenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J Clin Endocrinol Metab. 73:837-842.
11. Bliimel A, Oelkers W. 1974 Measurement of human plasma renin substrate concentration by angiotensin I radioimmunoassay: a discussion of methodical problems. J Clin Chem Clin Biochem. 12: 453-458.
12. Tuchelt H, Eschenhagen G, Bähr V, Schwietzer G, Thiede HM, Oelkers W. 1990 Role of atrial natriuretic factor in changes in the responsiveness of aldosterone to angiotensin II secondary to sodium loading and depletion in man. Clin Sci. 79:57-65.
13. Wahlefeld AW. 1972 Triglyceride, Bestimmung nach enzymatischer Verseifung. In: Bergemeyer HU, ed. Methoden der enzymatischen Analyse. Weinheim: Verlag Chemie; 1878-1882.
14. Friedewald WT, Levy RI, Fredrickson DS. 1972 Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of preparative centrifuge. Clin Chem. 18:499-502.
15. Realini JP, Goldzieher JW. 1985 Oral contraceptives and cardiovascular disease: a critique of the epidemiological studies. Am J Obstet Gynecol. 152:729-798.
16. Harlap S. 1991 Shortcomings in the data needed for risk-benefit estimates involving oral contraceptives and cardiovascular disease. Adv Contraception. 7(Suppl 3):54-64.
17. Poulter NR, Chang CL, Marmot M. 1991 Cardiovascular disease and contraception: what more can we leam from epidemiologic studies? Adv Contraception. 7(Suppl 3):65-83.
18. Royal College of General Practitioners. 1974 Oral contraceptives and health: an interim report. London: Piman.
19. Stampfer MJ, Willett WC, Colditz GA, Speizer FE, Hennekes CH. 1988 A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med. 319: 1313-1317.
20. Nichols M, Robinson G, Bounds W, Newman W, Guillebeaud J. 1993 Effect of four oral contraceptives on blood pressure in the pill-free interval. Contraception. 47:367-376.
21. Oelkers W, Schöneshöfer M, Bliimel A. 1974 Effects of progesterone and four synthetic progestagens on sodium balance and the renin-aldosterone system in man. J Clin Endocrinol Metab. 39: 882-890.
22. Beckerhoff R, Luetscher JA, Wilkinson R, Gonzales C, Nokes GW. 1972 Plasma renin concentration, activity, and substrate in hypertension induced by oral contraceptives. J Clin Endocrinol Metab. 34:1067-1073.
23. Derkx FHM, Stuenkel C, Schalekamp MPA, Visser W, Huisveld IH, Schalekamp MADH. 1986 Immunoreactive renin, prorenin, and enzymatically active renin in plasma during pregnancy and in women taking oral contraceptives. J Clin Endocrinol Metab. 63: 1008-1015.
24. s-angiotensin II in sodium replete and deplete man: effects on aldosterone, ACTH, cortisol, blood pressure and electrolyte balance. J Clin Endocrinol Metab. 46:402-413.
25. Wambach G, Braun B, Stimpel M, Kaufmann W. 1990 Basal and stimulated ANP levels during the normal menstrual cycle and on oral contraceptives [Abstract]. Acta Endocrinol (Copenh). 122(Suppl 1):127.
26. Skouby SO. 1991 Oral contraceptives and changes in glucose metabolism: clinical relevance? Adv Contraception. 7(Suppl 3):207-212.
27. Spellacy WN. 1982 Carbohydrate metabolism during treatment with estrogen, progestogen and low-dose oral contraceptives. Am J Obstet Gynecol. 142:732-734.